Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer

Molecular Therapy

Volumn 13, Issue 6, 2006, Pages 1185-1191

  Nemunaitis, John ^a,b   Meyers, Thomas ^b   Senzer, Neil ^a,b   Cunningham, Casey ^a,b   West, Howard ^c   Vallieres, Eric ^c   Anthony, Stephen ^d   Vukelja, Svetislava ^e   Berman, Barry ^f   Tully, Heather ^g   Pappen, Beena ^a   Sarmiento, Stephen ^a   Arzaga, Rosemarie ^a   Duniho, Steven ^g   Engardt, Susan ^g   Meagher, Madeleine ^g   Cheever, Martin A ^g  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d Cancer Care Northwest   (United States)

^e Tyler Cancer Center   (United States)

^f Cancer Centers of Florida   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

adenovirus; L523S; non small cell lung cancer; phase I; plasmid; vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNOGLOBULIN G; PLASMID VECTOR; PROTEIN L523S; RECOMBINANT DNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA VECTOR; DOSE RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN TISSUE; HYPERTENSION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LOOSE FECES; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; NAUSEA; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHASE 1 CLINICAL TRIAL; SKIN PRURITUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE;

EID: 33744479760     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.01.013     Document Type: Article

References (17)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
2. Winton T., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352 (2005) 2589-2597
3. Arriagada R., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350 (2004) 351-360
4. Kato H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350 (2004) 1713-1721
5. Strauss G.M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J. Clin. Oncol. 22 (2004) 621s
6. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev. Vaccines 4 (2005) 259-274
7. Trevor K.T., et al. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50 (2001) 397-407
8. Visseren M.J., et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int. J. Cancer 73 (1997) 125-130
9. Wentworth P.A., et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26 (1996) 97-101
10. Vitiello A., et al. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173 (1991) 1007-1015
11. Morse M.A. Technology evaluation: BLP-25, Biomira Inc. Curr. Opin. Mol. Ther. 3 (2001) 102-105
12. Mueller-Pillasch F., et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. 88 (1999) 95-99
13. Aguiar J.C., et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 20 (2001) 275-280
14. Wang R., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 98 (2001) 10817-10822
15. Williams J., et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 18 (2000) 1939-1943
16. Coulie P.G., and Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number?. Curr. Opin. Immunol. 17 (2005) 320-325
17. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11 (2005) 748-756